Skip to main content

Table 1 Characteristics of included and not included women living with HIV (WLWH) in Denmark from the Danish HIV Cohort Study (DHCS)

From: Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark – the SHADE

  WLWH included in the study WLWH not included in the study p-value
Number of individuals 334 (24.0) 1,058 (76.0) NA
Follow-up (years), median (IQR) 11.3 (5.9-16.9) 10.6 (5.5-15.9) 0.097
Follow-up time, total (person-years) 3,853 11,183 NA
Age at inclusion (years), median (IQR) 42.5 (36.8-48.3) 42.0 (35.5-48.2) 0.22
Race, n(%)    
 White 141 (42.6) 398 (39.5) 0.041a
 Asian 44 (13.3) 114 (11.3)
 Black 143 (43.2) 461 (45.7)
 Other 3 (0.9) 35 (3.5)
 (missing) (3) (50)
Place of HIV transmission, n(%)
 Denmark 114 (37.8) 326 (34.8) 0.11
 Europe + US 27 (8.9) 77 (8.2)
 Africa 128 (42.4) 416 (44.4)
 Asia 33 (10.9) 101 (10.8)
 Other 0 (0) 17 (1.8)
 (missing) (32) (121)
Mode of transmission, n(%)
 Heterosexual 294 (91.6) 799 (83.6) 0.0015
 IDU 16 (5.0) 106 (11.1)
 Other 11 (3.4) 51 (5.3)
 (missing) (13) (102)
Age at sexual debut (years),
mean (range) 17.3 (6–37) -b NA
Lifetime sexual partners, n(%)
  < 5 99 (29.6) -b NA
 5–14 135 (40.4)
 15–25 45 (13.5)
  > 25 53 (15.9)
 Does not wish to respond 2 (0.6)
 (missing) (0)
CD4 count at inclusion (cells/μL), n(%)
  < 200 12 (3.9) 79 (9.1) 0.012
 200–350 51 (16.5) 138 (15.9)
  > 350 247 (79.7) 650 (75.0)
 (missing) (24) (191)
HAART at inclusion, n(%)
 Yes 317 (94.9) 866 (81.8) <0.0001
 No 17 (5.1) 192 (18.2)
(missing) (0) (0)
On HAART with    
HIV RNA < 40 copies/mL, n(%)
 Yes 250 (83.6) 576 (75.5) 0.0042
 No 49 (16.4) 187 (24.5)
 (missing) (18) (103)
Cervical cytology within the past 1 year, n(%)c
 Yes 124 (37.1) 225 (21.3) <0.0001
 No 210 (62.9) 833 (78.7)
 (missing) (0) (0)
Cervical cytology within the past 3/5 years – depending on age for women age 23–65 years, n(%)d
 Yes 227 (67.7) 429 (40.6) <0.0001
 No 96 (28.7) 555 (52.5)
 Outside target age group 11 (3.3) 74 (7.0)
 (missing) (0) (0)  
Last cytology result, n(%)
 Normal 242 (72.5) 513 (48.5) <0.0001
 Abnormal 9 (2.7) 21 (2.0)
 No prior cytology obtained 83 (24.9) 524 (49.5)
HPV vaccination prior to inclusion, n(%)
 Yes (4-valent HPV vaccine) 4 (1.2) -b NA
 Yes (2-valent HPV vaccine) 0 (0)
 Yes (do not know name of vaccine) 1 (0.3)
 No 329 (98.5)
 (missing) (0)
  1. IDU intravenous drug user, NA not applicable, HAART Highly active antiretroviral therapy, HPV Human papillomavirus
  2. aThere was no difference in distribution of race between groups if the category “other” was removed from the “Race” variable (p = 0.45), bNo information available, cAs recommended in women living with HIV (we studied the past year + a 3-month grace period), dAs recommended in the general population, where women aged 23–49 years were invited for cervical cancer screening every third year and women aged 50–65 years every fifth year (we studied the past 3/5 years + a 3-month grace period)